Machine Learning-Based Prediction of SARS-CoV-2 Bioactivity: Integrating IC50 Regression and Activity Classification Using Multi-Task Neural Networks

Why It Matters

Accurately forecasting antiviral activity accelerates candidate selection and cuts laboratory expenses, giving pharma firms a competitive edge in pandemic response.

Key Takeaways

• Regression predicts IC50 with R² = 0.77
• Classification achieves 0.92 accuracy, precision, recall
• Multi‑task network jointly learns regression and classification
• Ligand efficiency used for activity prioritization
• Models reduce experimental screening costs

Pulse Analysis

Machine learning has become a cornerstone of modern drug discovery, especially as the COVID‑19 pandemic underscored the urgency of rapid antiviral development. Traditional high‑throughput screening demands extensive resources and time, limiting the number of compounds that can be evaluated. By leveraging computational models that learn structure‑activity relationships, researchers can virtually assess thousands of molecules, focusing laboratory effort on the most promising candidates and shortening the path from hit to lead.

The newly presented framework advances this paradigm by unifying three predictive tasks: quantitative IC50 regression, binary activity classification, and a multi‑task neural network that tackles both simultaneously. Using feature selection, the regression model reached an R² of 0.77, while a Random Forest classifier delivered 0.92 across accuracy, precision, and recall. Notably, the inclusion of ligand efficiency as a classification metric offers a nuanced view of potency relative to molecular size, a factor often overlooked in SARS‑CoV‑2 modeling. The multi‑task approach further boosts performance by sharing representations between tasks, improving interpretability and reducing the need for separate models.

For pharmaceutical companies and biotech startups, these results translate into tangible cost savings and faster decision cycles. Accurate in‑silico predictions enable early dismissal of low‑efficacy compounds, conserving reagents and labor. Moreover, the scalable nature of the models supports continuous integration into existing pipelines, facilitating rapid iteration as new viral variants emerge. As regulatory agencies grow comfortable with AI‑driven evidence, such integrated platforms are poised to become standard tools in antiviral research, accelerating the delivery of effective therapies to market.